Murdoch J, Hall R
Department of Anaesthesia, Dalhousie University, Halifax, Nova Scotia, Canada.
Can J Anaesth. 1990 Sep;37(6):663-71. doi: 10.1007/BF03006487.
Ischaemia, whether focal or global in nature, produces a sequence of intracellular events leading to increased cell permeability to water and ions including Ca++. There is a loss of cellular integrity and function, with increased production of prostaglandins, free radicals, and acidosis with lactate accumulation. These events may be exacerbated by glucose administration. Pharmacological agents aimed at alleviating ischaemic injury could be directed at decreasing cerebral metabolic requirements for oxygen, improving flow to ischaemic areas, preventing Ca+(+)-induced injury, inhibition of free radical formation, lactate removal, inhibition of prostaglandin synthesis, and prevention of complement-mediated leukocyte aggregation. Part I of this paper describes some of the pathophysiological events leading to ischaemic brain injury. Part 2 of this paper will consider the current agents available for brain protection.
局部或全身性缺血都会引发一系列细胞内事件,导致细胞对水和包括钙离子在内的离子的通透性增加。细胞完整性和功能丧失,同时前列腺素、自由基生成增加,伴有乳酸堆积导致酸中毒。葡萄糖输注可能会加剧这些情况。旨在减轻缺血性损伤的药物可用于降低大脑对氧气的代谢需求、改善缺血区域的血流、预防钙离子诱导的损伤、抑制自由基形成、清除乳酸、抑制前列腺素合成以及预防补体介导的白细胞聚集。本文第一部分描述了导致缺血性脑损伤的一些病理生理事件。本文第二部分将探讨目前可用于脑保护的药物。